- Home
- SM vs VKTX Comparison
SM vs VKTX Comparison
Compare SM & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SM
- VKTX
- Stock Information
- Founded
- SM 1908
- VKTX 2012
- Country
- SM United States
- VKTX United States
- Employees
- SM N/A
- VKTX N/A
- Industry
- SM Oil & Gas Production
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- SM Energy
- VKTX Health Care
- Exchange
- SM Nasdaq
- VKTX Nasdaq
- Market Cap
- SM 2.6B
- VKTX 2.8B
- IPO Year
- SM 1992
- VKTX 2015
- Fundamental
- Price
- SM $23.16
- VKTX $27.55
- Analyst Decision
- SM Buy
- VKTX Buy
- Analyst Count
- SM 11
- VKTX 12
- Target Price
- SM $43.90
- VKTX $84.00
- AVG Volume (30 Days)
- SM 2.6M
- VKTX 4.3M
- Earning Date
- SM 05-01-2025
- VKTX 04-23-2025
- Dividend Yield
- SM 3.46%
- VKTX N/A
- EPS Growth
- SM 11.97
- VKTX N/A
- EPS
- SM 7.14
- VKTX N/A
- Revenue
- SM $2,847,233,000.00
- VKTX N/A
- Revenue This Year
- SM $35.22
- VKTX N/A
- Revenue Next Year
- SM $0.17
- VKTX N/A
- P/E Ratio
- SM $3.24
- VKTX N/A
- Revenue Growth
- SM 24.88
- VKTX N/A
- 52 Week Low
- SM $19.67
- VKTX $18.92
- 52 Week High
- SM $51.94
- VKTX $81.81
- Technical
- Relative Strength Index (RSI)
- SM 47.00
- VKTX 53.68
- Support Level
- SM $20.81
- VKTX $26.37
- Resistance Level
- SM $24.18
- VKTX $30.28
- Average True Range (ATR)
- SM 1.13
- VKTX 1.65
- MACD
- SM 0.30
- VKTX 0.27
- Stochastic Oscillator
- SM 69.58
- VKTX 56.53
About SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.